Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
March 27, 2023 01:15 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is...
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
March 16, 2023 18:47 ET
|
Novartis Pharma AG
New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months...
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
March 07, 2023 08:01 ET
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre genehmigen die 26. Dividendenerhöhung in Folge auf CHF 3,20 (+3,2 %) pro Aktie für 2022; dies entspricht einer Rendite von 4.0 %1 und einer Ausschüttung von rund 61 %...
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
March 07, 2023 08:01 ET
|
Novartis Pharma AG
Les actionnaires approuvent la 26e augmentation consécutive du dividende à CHF 3,20 (+3,2%) par action pour 2022 ; représentant un rendement de 4.0%1 et une distribution du free cash-flow d’environ...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
March 07, 2023 08:01 ET
|
Novartis Pharma AG
Shareholders approve 26th consecutive dividend increase to CHF 3.20 (+3.2%) per share for 2022; representing a 4.0% yield1 and approximately 61% payout of free cash flow Shareholders confirm Joerg...
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
February 03, 2023 18:30 ET
|
Novartis Pharma AG
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16...
Novartis setzt Wachstumskurs mit weiterer Steigerung der Kerngewinnmarge fort und erreicht wichtige Innovations-meilensteine
February 01, 2023 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz stieg um +4% (kWk1, –2% USD), wobei sich das operative Kernergebnis um +8% (kWk, 0% USD) verbesserte Innovative Medicines (IM)...
Novartis poursuit sa croissance avec une nouvelle expansion de sa marge core et franchit des étapes importantes dans l’innovation
February 01, 2023 01:00 ET
|
Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RCExercice entier Chiffre d’affaires net en hausse de +4% (tcc1, -2% USD) et résultat opérationnel core croissant de +8% (tcc, 0% USD) Innovative Medicines...
Novartis continues to grow with further core margin expansion and achieves important innovation milestones
February 01, 2023 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income...
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
December 13, 2022 10:00 ET
|
Novartis Pharma AG
Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH) patients...